TARGETING TARGETED TREATMENT FOR IMMUNE AND NON-IMMUNE KIDNEY DISEASES.
Trans Am Clin Climatol Assoc
; 130: 88-99, 2019.
Article
em En
| MEDLINE
| ID: mdl-31516171
ABSTRACT
We have found that calcium calmodulin kinase IV is increased in T cells, podocytes, and mesangial cells from patients with systemic lupus erythematosus, as well as in lupus-prone mice, podocytes of patients with focal segmental glomerulosclerosis, and in mice injected with doxorubicin. We showed that this accounts for aberrant T cell function and glomerular damage. Using nanoparticles (nlg) loaded with a small drug inhibitor of calcium calmodulin kinase IV and tagged with antibodies directed to CD4 we have been able to show inhibition of autoimmunity and lupus nephritis. Also, using nlg tagged with antibodies to nephrin, we showed suppression of nephritis in lupus-prone mice and of glomerular damage in mice exposed to doxorubicin. We propose the development of approaches to deliver drugs to cells in a targeted and precise manner.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Sulfonamidas
/
Benzilaminas
/
Nefrite Lúpica
/
Glomerulosclerose Segmentar e Focal
/
Linfócitos T
/
Inibidores de Proteínas Quinases
/
Nanopartículas
/
Proteína Quinase Tipo 4 Dependente de Cálcio-Calmodulina
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Trans Am Clin Climatol Assoc
Ano de publicação:
2019
Tipo de documento:
Article